CAS 298708-81-3: Methyl (4R)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-5-pyrimidinecarboxylate

BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV)(IC50 : 53 nM).

Bay 41-4109 is a synthetic small molecule, which is a potent activator of soluble guanylate cyclase (sGC), derived from rational chemical design targeting specific signaling pathways. This compound primarily functions by binding to and stabilizing sGC in cells, enhancing the enzymatic conversion of GTP to cGMP, thereby modulating downstream signaling processes. Its mode of action facilitates the modulation of nitric oxide-mediated pathways, which are crucial in a variety of physiological processes. The uses and applications of Bay 41-4109 are of significant interest in the scientific community, particularly in the context of cardiovascular research and potential therapeutic approaches for conditions characterized by dysregulated nitric oxide signaling. The compound's ability to effectively increase cGMP levels makes it a valuable tool in pharmacological studies aimed at understanding the molecular mechanisms of vasodilation and the treatment of cardiovascular disorders. Additionally, its properties suggest potential applications in exploring therapeutic avenues for other diseases where sGC activation may prove beneficial.